Literature DB >> 32771263

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller, Laurence S Sperling.   

Abstract

Entities:  

Keywords:  ACC Expert Consensus Decision Pathway; GLP-1RA; SGLT2 inhibitor; atherosclerotic cardiovascular disease; cardiovascular risk reduction; diabetes; type 2 diabetes

Year:  2020        PMID： 32771263      PMCID： PMC7545583          DOI： 10.1016/j.jacc.2020.05.037

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  96 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

Authors:  Karen A Hicks; James E Tcheng; Biykem Bozkurt; Bernard R Chaitman; Donald E Cutlip; Andrew Farb; Gregg C Fonarow; Jeffrey P Jacobs; Michael R Jaff; Judith H Lichtman; Marian C Limacher; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Eric E Smith; Shari L Targum
Journal:  J Am Coll Cardiol       Date:  2014-12-29       Impact factor: 24.094

3.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

Authors:  Remo H M Furtado; Marc P Bonaca; Itamar Raz; Thomas A Zelniker; Ofri Mosenzon; Avivit Cahn; Julia Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Jose C Nicolau; Ingrid A M Gause-Nilsson; Martin Fredriksson; Anna Maria Langkilde; Marc S Sabatine; Stephen D Wiviott
Journal:  Circulation       Date:  2019-03-18       Impact factor: 29.690

4.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

5.  Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Authors:  Bernard Zinman; Vaishali Bhosekar; Robert Busch; Ingrid Holst; Bernhard Ludvik; Desirée Thielke; James Thrasher; Vincent Woo; Athena Philis-Tsimikas
Journal:  Lancet Diabetes Endocrinol       Date:  2019-03-01       Impact factor: 32.069

6.  Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.

Authors:  Wenjun Fan; Yang Song; Silvio E Inzucchi; Laurence Sperling; Christopher P Cannon; Suzanne V Arnold; Mikhail Kosiborod; Nathan D Wong
Journal:  Diabetes Obes Metab       Date:  2019-02-14       Impact factor: 6.577

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

8.  Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.

Authors:  Bernhard Ludvik; Juan P Frías; Francisco J Tinahones; Julio Wainstein; Honghua Jiang; Kenneth E Robertson; Luis-Emilio García-Pérez; D Bradley Woodward; Zvonko Milicevic
Journal:  Lancet Diabetes Endocrinol       Date:  2018-02-23       Impact factor: 32.069

Review 9.  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

10.  Standards of Medical Care in Diabetes-2020 Abridged for Primary Care Providers.

Authors: 
Journal:  Clin Diabetes       Date:  2020-01
View more
  75 in total

1.  Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?

Authors:  Debra Koenigsberger; Alexander Marquez; Pamela R Hughes
Journal:  J Fam Pract       Date:  2021-07       Impact factor: 0.493

Review 2.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.

Authors:  Xiaodan Wang; Jingyu Ni; Rui Guo; Lan Li; Jing Su; Feng He; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2021-03-12       Impact factor: 4.214

Review 3.  Diabetes in People with HIV.

Authors:  Sudipa Sarkar; Todd T Brown
Journal:  Curr Diab Rep       Date:  2021-03-17       Impact factor: 4.810

4.  Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?

Authors:  Sadiya S Khan; Mark D Huffman; Sanjiv J Shah
Journal:  Circ Heart Fail       Date:  2021-03-05       Impact factor: 8.790

Review 5.  Pharmacological treatment of hyperglycemia in type 2 diabetes.

Authors:  Simeon I Taylor; Zhinous Shahidzadeh Yazdi; Amber L Beitelshees
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

6.  The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.

Authors:  Naveen Seecheran; Arvinash Ramdeen; Niranjan Debideen; Kabeer Ali; Kathryn Grimaldos; Gabriella Grimaldos; Abhinav Karan; Rajeev Seecheran; Valmiki Seecheran; Sangeeta Persad; Harun Abdullah; Lakshmipathi Peram; Stanley Giddings; Shastri Motilal; Antonio Tello-Montoliu; David Schneider
Journal:  Cardiol Ther       Date:  2020-12-11

7.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.

Authors:  Hang-Long Li; Gregory-Y H Lip; Qi Feng; Yue Fei; Yi-Kei Tse; Mei-Zhen Wu; Qing-Wen Ren; Hung-Fat Tse; Bernard-M Y Cheung; Kai-Hang Yiu
Journal:  Cardiovasc Diabetol       Date:  2021-05-07       Impact factor: 9.951

Review 8.  Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review.

Authors:  Esther Artime; Irene Romera; Silvia Díaz-Cerezo; Elías Delgado
Journal:  Diabetes Ther       Date:  2021-05-03       Impact factor: 2.945

9.  Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.

Authors:  H Zhang; H Fu; X Fu; J Zhang; P Zhang; S Yang; Z Zeng; N Fu; Z Guo
Journal:  BMC Nephrol       Date:  2021-06-02       Impact factor: 2.388

10.  Adherence to a Healthy Lifestyle and the Risk of All-Cause Mortality and Cardiovascular Events in Individuals With Diabetes: The ARIC Study.

Authors:  Dongze Li; Yu Jia; Jing Yu; Yi Liu; Fanghui Li; Yanmei Liu; Qinqin Wu; Xiaoyang Liao; Zhi Zeng; Zhi Wan; Rui Zeng
Journal:  Front Nutr       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.